muscular

Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.

Vamorolone (VBP15) is an orally active dissociative steroidal anti-inflammatory drug and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone displays effective NF-κB inhibition and substantially decreases hormonal effects.

Ezutromid (BMN 195) is a translation modulator of Small utrophin (EC50: 0.4 uM). Ezutromid is an orally bioavailable small molecule that transcriptionally upregulates the utrophin gene, increasing both utrophin mRNA and protein. Through this action, Ezutromid increases muscle function in dystrophin-deficient MDX mice, a mouse model of muscular dystrophy.

Branaplam (LMI 070) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.

Neuromuscular-targeting compound 1 can be used to study muscular dystrophy and neuromuscular-related diseases.

Neuromuscular Disorder-Targeting Compound 1 is utilized in research for neuromuscular disorders, including chronic fatigue syndrome and fibromyalgia syndrome symptoms.

Apitegromab (SRK-015) is a new myostatin inhibitor, an antibody targeting myostatin precursor, which can be used to study neuromuscular diseases including spinal muscular atrophy.

SMN-C3 (MV8T2MCK57) is an orally active modulator of SMN2 splicing, and has the potential to treat spinal muscular atrophy (SMA).

Edasalonexent (CAT-1004) is an orally available NF-κB inhibitor designed to improve Duchenne muscular dystrophy.

CGP 3466B maleate (Omigapil maleate) is an orally bioavailable GAPDH nitrosylation inhibitor. Omigapil maleate abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD).

SMN-C2 is a selective regulator of SMN2 gene splicing, a risdiplam analogue, a selective RNA-binding ligand that regulates pre-mRNA splicing and acts by binding to SMN2 pre-mRNA.SMN-C2 has the potential to be used in the study of spinal muscular atrophy (SMA).

Methyl salicylate (Gaultheria oil) is an organic ester naturally produced by many species of plants, particularly wintergreens. For acute joint and muscular pain, methyl salicylate is used as a rubefacient and analgesic in deep heating liniments.

Tolperisone hydrochloride (Muscalm), a centrally acting muscle relaxant, is used in the therapy of pathologically increased tone of the cross-striated muscle resulted by neurological diseases (damage of the encephalomyelitis, myelopathy, multiple sclerosis, pyramidal tract) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.

Ataluren (PTC124) is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk.

Feprazone (DA-2370) possesses anti-inflammatory and antiadipogenic properties. Feprazone can be used in studies about the treatment of joint and muscular pain.

ART-CHEM-BB B025267 is the upregulator of utrophin production with EC50 of 1.8 μM and can be used in research on the treatment of Duchenne muscular dystrophy.

Suxibuzone (Suxibuzona) is a drug used for joint and muscular pain. It is a prodrug of the non steroidal anti inflammatory drug phenylbutazone, and is commonly used in horses.

RG7800 (RO6885247) has the potential for spinal muscular atrophy treatment. RG7800 is an SMN2 splicing modifier.

Adenylosuccinic acid (Adenylosuccinate) is a purine nucleotide cycle metabolite and a novel inducer of the Nrf2 cell protector. It can be used for research on Duchenne muscular dystrophy (DMD).

MA-0204 is a highly selective and orally available peroxisome proliferator-activated receptor δ (PPARδ) modulator (EC50s: 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively). It is a potential treatment for Duchene Muscular Dystrophy (DMD).

PMO-G is a spherical polymer micelle with skin permeability, capable of increasing dystrophin protein content in the abdominal muscle of mdx mice by up to 50-fold. PMO-G is utilized in research related to Duchenne muscular dystrophy.

Negamycin (hydrochloride) is a dipeptide antibiotic that can restore dystrophin expression in skeletal and cardiac muscles in the mdx mouse model of Duchenne muscular dystrophy (DMD). It binds to a segment of eukaryotic rRNA decoding site A. Negamycin (hydrochloride) is applicable in DMD research.

MF-DH-300 is a 15-PGDH inhibitor with an IC50 of 1.6 nM. It blocks the interaction between 15-PGDH and PGE2, promoting stem cell proliferation, increasing muscle strength, and enhancing mitochondrial function. Additionally, MF-DH-300 raises the expression of survival motor neuron (SMN) protein and is applicable in research on muscle diseases such as spinal muscular atrophy (SMA).

Etofenamate is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of joint and muscular pain.